Valeant Drops After Report Salix Sale Discussions Broke DownBy
Valeant Pharmaceuticals International Inc. dropped after a report that discussions to sell its gastrointestinal drugs unit to Japan’s Takeda Pharmaceutical Co. for about $10 billion have fallen apart.
Although the talks could still resume, Valeant is now focused on building the business, called Salix, rather than divesting it, Dow Jones reported, citing unidentified people familiar with the matter.
The shares dropped 6.5 percent to $16.02 at 10:20 a.m. in New York.
Scott Hirsch, a Valeant spokesman, declined to comment.
Valeant announced on Tuesday that it was making a “significant” expansion in the size of the sales force for gastrointestinal treatment Xifaxan, a sign that it had plans to keep the drug in-house. The Salix business is considered one of the drugmaker’s crown jewels.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.